Silence Therapeutics plc

OTCPK:SLNC.F Stock Report

Market Cap: US$1.0b

Silence Therapeutics Past Earnings Performance

Past criteria checks 0/6

Silence Therapeutics's earnings have been declining at an average annual rate of -18.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 58% per year.

Key information

-18.6%

Earnings growth rate

-10.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate58.0%
Return on equity-253.8%
Net Margin-170.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Silence Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:SLNC.F Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2325-432144
30 Sep 2328-432042
30 Jun 2329-412142
31 Mar 2323-432141
31 Dec 2218-402036
30 Sep 2216-362234
30 Jun 2216-392134
31 Mar 2215-392131
31 Dec 2112-392031
30 Sep 2111-422130
30 Jun 2110-421826
31 Mar 218-351523
31 Dec 205-331420
30 Sep 203-261020
30 Jun 201-221024
31 Mar 201-211018
31 Dec 190-201013
30 Sep 190-19107
30 Jun 190-18110
31 Mar 190-18110
31 Dec 180-18110
30 Sep 180-1290
30 Jun 180-580
31 Mar 180-370
31 Dec 170-260
30 Sep 170-560
30 Jun 171-950
31 Mar 171-940
31 Dec 161-840
30 Sep 160-840
30 Jun 160-730
31 Mar 160-730
31 Dec 150-730
30 Sep 150-830
30 Jun 150-1030
31 Mar 150-1030
31 Dec 140-1130
30 Sep 140-1140
30 Jun 140-1140
31 Mar 140-1040
31 Dec 130-940
30 Sep 130-830
30 Jun 130-630

Quality Earnings: SLNC.F is currently unprofitable.

Growing Profit Margin: SLNC.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SLNC.F is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare SLNC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLNC.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: SLNC.F has a negative Return on Equity (-253.77%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.